Navigation Links
Cannabis Compound May Stop Metastatic Breast Cancer

But patients can't get enough CBD from just smoking pot, scientists add

MONDAY, Nov. 19 (HealthDay News) -- A non-toxic, non-psychoactive compound in marijuana may block the progress of metastatic breast cancer, according to a new study by researchers in California.

"This is a new way to treat a patient that is not toxic like chemotherapy or radiotherapy. It is a new approach for metastatic cancer," said lead researcher Sean D. McAllister, an associate scientist at the California Pacific Medical Center Research Institute in San Francisco.

The compound found in cannabis, called cannabidiol (CBD), inhibits a gene, Id-1, that researchers believe is responsible for the metastatic process that spreads cells from the original tumor throughout the body.

Opting for a musical metaphor, senior researcher Pierre-Yves Desprez likened Id-1 to "an [orchestra] conductor. In this case, you shoot the conductor, and the whole orchestra is going to stop. If you shoot the violinist, the orchestra just continues to play."

In humans, the Id-1 gene is found only in metastatic cancer cells, said Desprez, a staff scientist at the institute. Before birth, they are present and involved in the development of human embryos, but after birth, they go silent -- and should stay that way, he said.

But in metastatic cancer "when [the genes] wake up, they are very bad," he said. "They push the cells to behave like embryonic cells and grow. They go crazy, they proliferate, they migrate." Desprez said, "We need to be able to turn them off."

According to the study, CBD does exactly that.

"We are focusing on the latest stages of cancer," Desprez added. The cancer cell itself is not the problem, because a tumor can be "removed easily by surgery," he said. The problem is the development of metastatic cells which is "conducted" by Id-1.

McAllister and Desprez said they are not suggesting that patients with hormone-independent metastatic breast cancer smoke marijuana. For one thing, a sufficient amount of CBD could never be obtained in that way, they said.

The research that has been done on marijuana and its compounds, however, is helpful, McAllister, said. CBD has been around for a long time, and researchers have found it is not psychoactive, and its "toxicity is very low," he added.

The new findings are published in the November issue of Molecular Cancer Therapeutics.

If McAllister's and Desprez's work results in the development of a cancer treatment, someone with metastatic cancer might be placed on CBD for several years. That means low toxicity is important, McAllister explained.

McAllister also suggested that Id-1 is "so important in providing the [metastatic] mechanism in these cells in so many types of cancers" that they "provide us an opportunity potentially to target other types of cancers."

The study's findings were "were a serendipitous discovery, in a way," McAllister said. Desprez noted that he had been working on the Id-1 gene for 12 years. His lab had demonstrated that it was a key gene for invasive breast cancer and tumor progression, and Desprez had found a way to inhibit it in mice, but not in humans.

Then, two years ago, McAllister -- an expert on cannabinoids -- and Desprez, a cancer researcher, started to work together. Through their combined forces "what we found is actually what I was looking for for the last 12 years," Desprez said.

Further study is needed before CBD can be conclusively identified as a treatment option, McAllister and Desprez said. "We need to involve a team of physicians, because we are bench [basic] scientists," McAllister said.

One expert called the findings intriguing but preliminary.

"This is the first evidence that a cannabinoid can target the expression of an important breast cancer metastasis gene," noted Manuel Guzman, a Spanish expert on cannabinoids and cancer. He described the California study as giving "preliminary insight into the question of whether CBD could be used clinically to treat metastatic breast cancer."

However, "all the experiments in the paper have been conducted in cultured cells and none of them in any animal model of breast cancer, which would be one of the steps for further research," added Guzman, who is a professor of biochemistry and molecular biology at Complutense University in Madrid.

Guzman also noted that "Id-1 is just one of many genes involved in breast cancer metastasis" and that future research also needs to examine the impact of CBD on these other metastasis genes.

More information

There's more on breast cancer at the U.S. National Cancer Institute.

SOURCES: Sean D. McAllister, Ph.D., associate scientist, California Pacific Medical Center Research Institute, San Francisco; Pierre-Yves Desprez, Ph.D., staff scientist, California Pacific Medical Center Research Institute, San Francisco; Manuel Guzman, Ph.D., professor, biochemistry and molecular biology, Complutense University, Madrid, Spain; November 2007, Molecular Cancer Therapeutics

Copyright©2007 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Role seen for cannabis in helping to alleviate allergic skin disease
2. Smoked cannabis proven effective in treating neuropathic pain
3. Emotional Intelligence and the use of tobacco and cannabis
4. Coloring Compound in Fruits, Veggies May Cut Colon Cancer Risk
5. Sugary Sodas High in Diabetes-Linked Compound
6. Red wine compound shown to prevent prostate cancer
7. CutisPharma Selected by Medicine Shoppe International as Preferred Vendor for Unit-of-Use Compounding Kits
8. A Chinese medicine compound has satisfactory anti-cancer effects on hepatocellular carcinoma
9. VioQuest to Present Data on Oncology Compounds VQD-002 and Lenocta(TM) at AACR-NCI-EORTC International Meeting
10. Organon Signs an Exclusive, Worldwide Licence Agreement on Advanced Antithrombotic Compounds With Endotis Pharma
11. Primus Innovations and Health Robotics Launch Strategic Partnership to Accelerate Transformation in Chemotherapy Compounding
Post Your Comments:
Related Image:
Cannabis Compound May Stop Metastatic Breast Cancer
(Date:11/25/2015)... ... November 25, 2015 , ... “While riding the bus, I ... Bronx, N.Y. “I thought there had to be a convenient and comfortable way to ... The PROTECTOR enables disabled individuals to safely travel during cold or inclement weather. In ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care ... disease. The Periwinkle Pioneers, nominated by the public, will receive special recognition throughout ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... philanthropic seniors, is resulting in a way for homeless people to have a ... have launched a new initiative whereby they are repurposing plastic bags into sleeping ...
(Date:11/25/2015)... ... November 25, 2015 , ... Since its launch in 2012, ... adult stem cell therapies to patients with chronic degenerative medical conditions. Now, the ... Registered Trademark (RTM). , Organizations are required to hold a registered trademark in ...
(Date:11/24/2015)... ... November 25, 2015 , ... Genesis Chiropractic Software ... software creates an agreement between the practice owner and the patient that automatically ... notification, and projections. Click here to learn more. , ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... FRANCISCO , Nov. 24, 2015  Thanks to ... Dignity Health St. Mary,s Medical Center,s Sister Diane Grassilli ... breast imaging capabilities in San Francisco ... an anonymous friend, stepped forward with a gift of ... for Breast Digital Mammography with Tomosynthesis and Whole Breast ...
(Date:11/24/2015)... Colo. , Nov. 24, 2015  Array ... that its Chief Executive Officer, Ron Squarer ... Healthcare Conference in New York.  The public is ... webcast on the Array BioPharma website.Event:Piper Jaffray Annual ... , Wednesday, December 2, 2015Time:1:30 p.m. Eastern Time ...
(Date:11/24/2015)... HOUSTON, TX and VANCOUVER, Nov. 24, 2015 /PRNewswire/ ... EPI; NASDAQ: EPIX ) announced today that the ... clinical study of EPI-506 as a treatment for metastatic ... States and Canada.  --> ... --> In the Phase 1/2 clinical trial, ...
Breaking Medicine Technology: